2023 World Conference on Lung Cancer (Posters)-EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China

EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the real-world treatment patterns and clinical outcomes for advanced non-small cell lung cancer (NSCLC) patients in China who have epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20Ins). The study included 116 patients from two state-level cancer hospitals in China.<br /><br />The findings revealed that the prognosis for advanced NSCLC patients with EGFR ex20ins in China was poor, highlighting the need for novel therapies in this patient population. The study showed that the median overall survival for these patients ranged from 16.5 to 17.8 months. It also showed that the majority of patients received platinum-based chemotherapy as their first line of treatment, while a small percentage received EGFR tyrosine kinase inhibitors (TKIs).<br /><br />The study also evaluated the real-world progression-free survival (PFS) for each line of therapy. The median real-world PFS for the first line of therapy was 6.2 months, and for the second line of therapy, it was 4.2 months for patients who received post-platinum treatments. The confirmed objective response rates were 14.8% for patients with the first line of therapy and 10.0% for patients with the post-platinum second line of therapy.<br /><br />However, the study has some limitations. It relied solely on data recorded in medical records, which may have resulted in missing data. Additionally, complete death information was lacking from the medical charts, which could have impacted the assessment of clinical outcomes.<br /><br />Overall, this study addressed a critical gap in knowledge about the real-world treatment patterns and clinical outcomes for advanced NSCLC patients with EGFR ex20Ins in China. The findings highlight the need for further research and the development of novel therapies for this patient population.

Asset Subtitle

Yan Wang

Meta Tag

Speaker Yan Wang

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

NSCLC

China

EGFR exon 20 insertion mutations

prognosis

novel therapies

overall survival

platinum-based chemotherapy

progression-free survival

objective response rates

patient population